INTRODUCTION
Hematogones were first described in the 1930s as lymphoid-appearing cells present in the sternal aspirates of children undergoing evaluation for an assortment of neoplastic, congenital, infectious, and autoimmune diseases [1, 2] . Although their biologic significance was unclear, authors speculated on their role in hematopoiesis, with some considering hematogones to be undifferentiated primordial cells (hemocytoblasts) [1] [2] [3] . Eventually, the name hematogone, from hematogonia (''blood-maker'' in Latin), was adopted [1, 2] . Since that time, numerous studies document that they represent B-lymphocyte precursors that reside in the marrow and that undergo an orderly maturation sequence to give rise to mature B cells [4] [5] [6] [7] [8] [9] [10] . By flow cytometry, hematogones have been characterized into several stages using CD10, CD19, CD20, CD22, CD34 and CD38 [9] . Although this method is very effective in characterizing the maturational spectrum of hematogones, the wide variation in flow cytometry protocols limits the determination of cell percentages; therefore, assessment by morphology is standard for all current classification systems [11] .
Hematogones may be increased in numerous neoplastic as well as nonneoplastic conditions including marrow regeneration and immune deficiencies [4, [6] [7] [8] [9] [10] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] . One situation where increased percentages of hematogones are commonly observed is in the post-umbilical cord blood transplantation (UCBT) setting [17, 22, 23] . UCBT has been shown to have high numbers and increased generative capacity of B-lymphocyte progenitors [24] . For unknown reasons, elevated hematogone percentages are noted in some but not other UCBT patients. Whether there is a prognostic association between the presence of bone marrow (BM) hematogones and clinical outcomes in UCBT is unknown. This lack of information may explain why hematogones are not routinely reported in BM differential counts and are, instead, combined with other lymphocytes.
To date, no study has assessed the reproducibility of morphologic detection of hematogones in the BM of transplantation recipients or whether hematogone percentages are associated with posttransplantation outcomes. Considering that hematogones give rise to B cells that provide protection against pathogens and that in nontransplantation patients, the percentage of hematogones in the BM is inversely correlated with the percentage of leukemic blasts in the marrow [9, 25] , we hypothesized that increased hematogones would be associated with superior transplantation outcomes.
To address this hypothesis, we assessed the percentage of BM hematogones in a cohort of 91 consecutive patients with acute myelogenous leukemia (AML) treated with allogeneic single or double UCBT. Recognizing that any associations between hematogones and clinical outcomes are only useful if they can be reproducibly recognized, we also determined the correlation between two independent observers in the assessment of the percentage hematogones in the marrow aspirates at day 21 and day 100 after transplantation.
METHODS Patients
Ninety-one consecutive patients with AML undergoing myeloablative UCB transplantation were studied. We included patients who had undergone UCB transplantation at the University of Minnesota between February 1999 and July 2008. Patients were required to have a BM biopsy with no evidence of relapse at the time of the marrow analysis. Hematogone determinations were performed on day 21 and 100 post-UCB transplantation (ie, day 21 or 100) samples. Patients who relapsed between day 21 and day 100 were censored for the day-100 hematogone determination. Because of the morphologic similarity between hematogones and leukemic lymphoblasts, only patients with AML were included in this analysis. Of 91 eligible patients with AML receiving UCBT during the study period, three were excluded due to early posttransplantation relapse (n 5 2) or lack of availability of any interpretable slides for review (n 5 1). A summary of exclusion criteria is provided in Supplemental Table 1 , online only. Of the 88 remaining patients, 85 had interpretable slides available for review at day 21. Sixty-six cases were available for review at both day 21 and day 100, whereas 19 cases were reviewed at only day 21, and three cases were reviewed only at day 100. Overall, 154 cases from 88 patients (88 of 91) fit the above criteria and had material adequate for differential counts.
Morphologic Analysis
Wright-Giemsa stained direct and concentrate BM aspirate smears and trephine touch imprint preparations were each reviewed independently by a faculty hematopathologist (V.J.D.) and pathology resident (T.J.H.). The specimens used to perform differential counts were, in order of preference, direct smears, touch preparations, and concentrate smears. In general, touch preparations were used in cases in which aspirates were hemodilute or not available. Concentrate smears were used in cases with hypocellular aspirates. Before the beginning of the study, both reviewers concurrently examined several cases noted to have high percentages of hematogones and came to agreement on morphologic features useful in distinguishing hematogones from mature lymphocytes. A 500-cell differential count, including hematogones, was performed in each case, except in instances where low cellularity precluded a full 500-cell count. In those cases, a 50-to 300-cell differential count was performed. A 50-cell differential count was performed in one case only, on a concentrate smear. Hematogones had condensed and homogenous nuclear chromatin without significant clumping, high nuclear-to-cytoplasmic (N/C) ratios with a thin rim of eccentric basophilic cytoplasm, and no cytoplasmic vacuoles, inclusions, or granules. When present, nucleoli were indistinct. In contrast, mature lymphocytes had coarse, clumped chromatin, lower N/C ratios and more abundant cytoplasm with variable cytoplasmic inclusions and granules (Figure 1 ).
Interobserver Variability in the Morphological Assignment of Hematogones
In 146 of 154 cases (94.8%), the hematogone percentages reported by the two observers were within 3.6%. The remaining eight cases (5.2%) were jointly reviewed, and a consensus was reached after which interobserver variability for percent hematogones reported at days 21 and 100 was calculated using Pearson correlation. Correlation coefficients at days 21 and 100 were 0.83 and 0.98, respectively (P # .01 for both) [26] . For the analysis (to follow) correlating hematogone percentage with transplantation outcomes, the average percentage from the two reviewers was used.
Flow Cytometric Immunophenotyping
The clinical laboratory database for all patients with slides available for microscopic review was searched in order to determine whether flow cytometric immunophenotyping was performed on the marrow aspirate and whether a percentage value for hematogones was reported at the time of the original study. Flow cytometry was performed on BM aspirates that were collected in sodium heparin. After lysis of erythrocytes (ammonium chloride), the cells were washed twice with phosphate-buffered saline and stained according to the manufacturers' recommendations with a panel of monoclonal antibodies directly conjugated to fluorochromes (B.D. Biosciences, San Jose, CA). Data were acquired on a FACSCaliber (B.D. Biosciences) using CELL Quest Pro and analyzed using FACS Diva software.
Assessment of Patient Absolute Lymphocyte Count
The medical records were reviewed for patients, and absolute lymphocyte counts (ALCs) were obtained as previously described [27] . Briefly, ALCs were collected from the medical records at day 30 (13 days). ALCs were recorded as missing if the WBC was \0.5 Â 10 9 /L, as no manual differential counts were performed during severe leukopenia. Correlation between average percentage hematogone and ALC was performed using X 2 analysis.
Statistical Analysis
Data on transplantation patient characteristics, posttransplantation complications and outcomes were prospectively collected by the Biostatistical Support Group at the University of Minnesota using standardized collection procedures. Details regarding graft selection, conditioning regimens, and graftversus-host disease (GVHD) prophylaxis have been previously described [28] [29] [30] . Patients and disease characteristics were summarized using descriptive statistics. Statistical comparisons of these variables between high and low hematogone percentage were completed by a nonparametric Wilcoxon test for continuous factors and Pearson X 2 test for categorical factors. All patients were followed longitudinally until death or last follow-up. The endpoints included neutrophil and platelet recovery, overall survival (OS), disease-free survival (DFS), transplantation-related-mortality (TRM), risk of relapse, acute GVHD (aGVHD), and chronic GVHD (cGVHD). Kaplan-Meier [31] was used to estimate neutrophil recovery, OS, and DFS. Cumulative incidence [32] was used to estimate platelet recovery, relapse, TRM, aGVHD, and cGVHD. Statistical comparison of neutrophil, OS, and DFS between groups was completed by the log-rank test. The proportional hazards model of Fine and Gray [33] was used to assess the independent factors on platelet recovery, relapse, TRM, aGVHD, and cGVHD. Factors included in multivariate analysis were hematogone percentage (low vs high), donor number (single vs double), recipient age (\21 vs $21), recipient cytomegalovirus (CMV) status (negative vs positive), total, postthaw CD34 (\0.50 vs $0.50), total, postthaw colony-forming unit (\0.042 vs $0.042), and total nucleated cell (\0.38 vs $0.38). The backward stepwise method was used to decide the final model. Groups with a P value of #.05 were considered to be statistically different.
RESULTS

Percentage Marrow Hematogones and Transplantation Outcomes
Patients were grouped into quartiles based on the average percentage of BM hematogones (determined using morphology by two reviewers) at day 21 and day 100 after transplantation. In univariate analysis, those in the lowest quartile had differing outcomes compared to patients in the upper three quartiles (not shown). Based on these findings, patients were grouped using the 25th percentile (0% at 21 days after UCBT and 0.9% at 100 days after UCBT) as a cutoff. There were no demographic differences between patients who had a low or high percentage of hematogones at day 21 (Supplemental Table 2 , online only) or day 100 (Table 1) .
At day 121 after transplantation, the percentage of marrow hematogones varied from 0% to 10.8% (n 5 91). In assessing these percentages, we observed that patients in the lowest quartile (corresponding to those with hematogones 5 0%) were more likely to develop grade III to IV aGVHD (38%, 95% confidence interval [CI], 20%-57% vs 22%; 95% CI, 11%-32%; P 5 .05). This association was confirmed in multivariate analysis where patients with hematogones in the lowest quartile were more likely to develop severe aGVHD (P 5 .01) ( Table 2) . Based on multivariate analysis, hematogone percentages at day 21 were not associated with OS, DFS, TRM, neutrophil engraftment, platelet engraftment, or cGVHD (Table 2 ). In multivariate analysis, patients in the upper three quartiles (with hematogone percentages .0) had a relative risk of relapse of 8.48 (95% CI, 0.82-88.06) compared to those with hematogones 5 0 (P 5 .07) ( Table 2) . Patients who had a high BM hematogone percentage at day 21 tended to have a high percentage at day 100 as well. More specifically, of the 66 patients who had hematogone analysis at both day 21 and day 100, 47 patients at day 21 had a hematogone percentage of .0. Forty of these patients (85%) remained in the high hematogone group at day 100 (P 5 .01).
At day 1100 after transplantation, the percentage of hematogones varied from 0% to 29.6% (n 5 66). At this time, the percentage of hematogones was more strongly associated with transplantation outcomes. In univariate analysis, patients with high hematogone percentages (ie, upper three quartiles [. 5 0.9%]) had a 3-year OS of 76% (95% CI, 61%-85%) compared to 49% (95% CI, 61%-85%) for those with hematogone percentages in the lowest quartile (\0.9%; P 5 .02) ( Figure 2A ). As shown in Table 3 , this was confirmed in multivariate analysis, where patients with a high percentage of hematogones in the marrow were five-fold more likely to survive (relative risk [RR], 0.20; 95% CI, 0.05-0.76; P 5 .02). This improvement in OS was due to a reduction in TRM. In univariate analysis, patients with a high hematogone percentage ($0.9%) at day 100 showed a 1-year TRM rate of 2% (95% CI, 0%-6%) compared to 31% (95% CI, 9%-54%; P \ .01) ( Figure 2B ). This was again confirmed in multivariate analysis (Table 3) , where increased hematogone percentages ($0.9%) at day 100 were associated with a relative risk of TRM of 0.03 (95% CI, 0-0.34; P # .01). Hematogone percentages at day 100 were not associated with DFS, relapse, neutrophil engraftment, platelet engraftment, or cGVHD on multivariate analysis (Table 3) .
Morphologic Correlation with FACS Assessment of Hematogones
Review of the laboratory database showed that prior to 2007, flow cytometric immunophenotyping was rarely performed on BM aspirates of post-UCBT patients with AML at our center. Flow cytometric immunophenotyping included a percentage hematogones in the final report for 11 of the flow cytometry cases. As shown in Figure 3 , hematogone determination by flow cytometry was correlated with that determined by morphology (P 5 .05) in the limited cases where data were available.
Marrow Hematogone Percentage is not Associated with Absolute Lymphocyte Count
We have recently determined that rapid lymphocyte recovery after UCBT is associated with improved transplantation outcomes [27] . In that study, patients treated with myeloablative transplantation showed superior outcomes (OS, PFS, and TRM) if their ALC was .200 Â 10 6 /L at day 130. We hypothesized that ALC and percentage marrow hematogones would be correlated at day 21 and/or day 100. As shown in Table 4 , ALC at day 30 was available in the medical records for 61 patients at day 21 and 56 patients at day 100. Surprisingly, there was no correlation between ALC and hematogone percentage in the marrow at either day 21 or day 100. Thus, hematogone percentage is independent of ALC (P 5 .86 and .12, respectively), but both are associated with UCBT outcomes (above and [27] ).
DISCUSSION
We investigated whether the percentage of marrow hematogones as determined by morphology was associated with UCBT outcomes in a population of uniformly treated adults and children with AML. Our results show that increased percentages of hematogones in the BM at day 21 were associated with lower rates of grade III to IV aGVHD, likely suggesting that severe aGVHD interferes with B cell reconstitution.
At day 100, high percentages of hematogones were associated with improved 3-year OS, due to lower 1-year TRM. Although recent studies show a relationship between the presence of hematogones detected by flow cytometry and improved OS in patients with AML receiving chemotherapy, multivariate analysis could not confirm those findings [34] . Our study demonstrates that increased numbers of hematogones are an independent predictor of OS and TRM in a subset of patients with AML undergoing UCBT. We specifically chose patients with AML for this study due to the concern for morphologic similarity between hematogones and lymphoblasts. Thus, additional studies are needed to investigate whether increased marrow hematogones are associated with similar outcomes in other diseases, including acute lymphoblastic leukemia or lymphoma.
In this study, only a limited number of cases were reviewed by flow cytometry considering that BM flow cytometry for AML was not the standard of care at the time of the study. However, of the limited cases, there was adequate correlation between morphology and flow cytometry. Based on this, and because the relative quantification of marrow constituents using flow cytometry is problematic, we chose to assess hematogones using morphology in this study. Current concerns for using flow cytometry include that some cell types, such as erythroid precursors, are lost when a lysis step is incorporated. This would artificially increase hematogone percentages. Likewise, various gating strategies may include cells that do not represent hematogones, or alternatively may exclude true hematogones. This would artificially increase or decrease the calculated hematogone percentage, respectively.
In addition, samples submitted for flow cytometry often represent the second aspirated specimen and are hemodilute, artificially lowering hematogone percentages. Thus, we chose to perform morphologic assessment as the ''gold standard'' for quantification of marrow hematogones. As flow cytometry becomes more standardized across institutions, future studies should be performed to determine whether this modality is also associated with transplantation outcomes. While we provide evidence that marrow hematogones are associated with UCBT outcomes, there are limitations to this study. First, this is a single-institution study, which may introduce not only patient bias, but also subjectivity in the assessed morphologic parameters. Another potential limitation relates to specimen preparation. All direct smears were prepared at the bedside during the marrow aspirate procedure by hematology technicians and were stained by hand. This method, in our experience, facilitates a more accurate assessment of the BM cellular composition. In contrast, anticoagulated specimens processed by automated machine stainers may preclude accurate assessment of the cellular constituents, limiting the applicability of these findings.
One of the largest causes of mortality in patients undergoing UCBT is infections, predominantly during the lymphopenic period [35] . Although we demonstrate that increased percentages of marrow hematogones correlate well with clinical outcomes, it is not clear that their increase predicts immunity or that immunity from infection is the explanation for improved outcomes. In fact, in a subset of patients, there was no correlation of BM hematogone percentages with serum immunoglobulin levels at 100 or 365 days after transplantation (not shown). Likewise, detailed B cell immunological reconstitution was not routinely performed on this cohort; therefore, how these data are related to mature B cell recovery will be the subject of additional studies.
In summary, patients with AML undergoing UCBT with increased BM hematogones have less aGVHD, less TRM, and improved OS. Additional prospective studies are needed in other diseases because these results could become a useful tool to predict posttransplantation outcomes. 
